Indapta Therapeutics
Phase 1Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat cancer and autoimmune diseases.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $57M
About
Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat cancer and autoimmune diseases.
Cell & Gene Therapy
Funding History
2Total raised:$57M
Series A$49MOct 15, 2021
Seed$8MMay 15, 2020